{"result": "(\"entity\"<|>GLUCEMIA<|>EVENT<|>Glucemia refers to the concentration of glucose in the blood, which is typically measured in mg/dl and is crucial for diagnosing various metabolic conditions.)\n##\n(\"entity\"<|>GSDIII<|>EVENT<|>Glycogen Storage Disease Type III (GSDIII) is a metabolic disorder caused by the deficiency of the enzyme amilo-1,6-glucosidase, leading to various health complications.)\n##\n(\"entity\"<|>HEPATOMEGALIA<|>EVENT<|>Hepatomegalia is the enlargement of the liver, which is a common symptom in patients with GSDIII.)\n##\n(\"entity\"<|>HIPOTONÍA<|>EVENT<|>Hypotonia is a condition characterized by decreased muscle tone, often seen in patients with GSDIII.)\n##\n(\"entity\"<|>HIPERTRIGLICERIDEMIA<|>EVENT<|>Hipertrigliceridemia is a condition of elevated triglycerides in the blood, frequently observed in GSDIII patients.)\n##\n(\"entity\"<|>CIRROSIS<|>EVENT<|>Cirrhosis is a late-stage liver disease characterized by scarring of the liver, which is rare in GSDIII patients.)\n##\n(\"entity\"<|>ADENOMAS HEPÁTICOS<|>EVENT<|>Hepatic adenomas are benign tumors of the liver that can occur in patients with GSDIII, though they are infrequent.)\n##\n(\"entity\"<|>HEPATOCARCINOMA<|>EVENT<|>Hepatocarcinoma is a type of liver cancer that can develop in patients with GSDIII, occurring in less than 10% of cases.)\n##\n(\"entity\"<|>OSTEOPENIA<|>EVENT<|>Osteopenia is a condition of lower than normal bone density, which can be a long-term complication of GSDIII.)\n##\n(\"entity\"<|>SÍNDROME DE OVARIO POLIQUÍSTICO<|>EVENT<|>Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that can occur in female patients with GSDIII.)\n##\n(\"entity\"<|>MUSCULATURA CARDÍACA<|>EVENT<|>Cardiac muscle refers to the muscle tissue of the heart, which can be affected in GSDIII patients, leading to cardiomyopathy.)\n##\n(\"entity\"<|>MUSCULATURA ESQUELÉTICA<|>EVENT<|>Skeletal muscle is the muscle tissue that is attached to bones, which can also be affected in GSDIII patients.)\n##\n(\"relationship\"<|>GSDIII<|>HEPATOMEGALIA<|>Hepatomegalia is a common symptom associated with GSDIII, indicating liver enlargement due to glycogen accumulation.<|>8)\n##\n(\"relationship\"<|>GSDIII<|>HIPOTONÍA<|>Hypotonia is a frequent manifestation in patients with GSDIII, reflecting muscle weakness.<|>8)\n##\n(\"relationship\"<|>GSDIII<|>HIPERTRIGLICERIDEMIA<|>Hipertrigliceridemia is often observed in GSDIII patients, indicating metabolic dysregulation.<|>8)\n##\n(\"relationship\"<|>GSDIII<|>CIRROSIS<|>Cirrhosis is a rare complication in GSDIII patients, highlighting the potential severity of the disease.<|>3)\n##\n(\"relationship\"<|>GSDIII<|>ADENOMAS HEPÁTICOS<|>Hepatic adenomas can develop in GSDIII patients, although they are infrequent.<|>3)\n##\n(\"relationship\"<|>GSDIII<|>HEPATOCARCINOMA<|>Hepatocarcinoma is a potential risk in GSDIII patients, occurring in less than 10% of cases.<|>3)\n##\n(\"relationship\"<|>GSDIII<|>OSTEOPENIA<|>Osteopenia can be a long-term complication of GSDIII, affecting bone health.<|>4)\n##\n(\"relationship\"<|>GSDIII<|>SÍNDROME DE OVARIO POLIQUÍSTICO<|>Polycystic Ovary Syndrome can occur in female patients with GSDIII, indicating hormonal imbalances.<|>4)\n##\n(\"relationship\"<|>GSDIII<|>MUSCULATURA CARDÍACA<|>Cardiac muscle can be affected in GSDIII patients, leading to conditions like hypertrophic cardiomyopathy.<|>6)\n##\n(\"relationship\"<|>GSDIII<|>MUSCULATURA ESQUELÉTICA<|>Skeletal muscle is also impacted in GSDIII, resulting in muscle weakness and atrophy.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: es raro en\ntener glucemias entre 70-95 mg/dl. En adolescentes                    el período neonatal), con hepatomegalia (98%), hipo-\nsuele ser suficiente con 2 mg/kg/min de glucosa si es                 glucemia cetósica (53%), fallo de medro (49%) y disli-\nque aún precisan soporte enteral nocturno.                            pemia, sobre todo hipertrigliceridemia (>80% de pa-\n                                                                      cientes, pero menos grave que en la GSDI), lo que hace\n1.3.    Déficit de amilo-1,6-glucosidasa,                             de entrada indistinguibles ambas patologías. Con el\n        glucogenosis tipo III o enfermedad                            paso de los años esta clínica mejora y habitualmente se\n        de Cori (GSDIII)                                              normaliza tras la pubertad, debido a la disminución de\n                                                                      los requerimientos de glucosa y a la fibrosis hepática,\n1.3.1.     Fisiopatología y diagnóstico                               aunque es muy raro que ésta progrese a cirrosis. La\n                                                                      aparición de adenomas hepáticos o hepatocarcinoma\n   La GSDIII constituye un grupo de patologías produ-                 ocurre en menos del 10% de los pacientes, y también\ncidas por la afectación de alguna de las isoformas de la              son infrecuentes la hiperuricemia y la afectación renal.\nenzima desramificadora del glucógeno amilo-1,6-glu-                   Las complicaciones a largo plazo incluyen osteopenia/\ncosidasa (gen AGL, 1p21.2). Su incidencia estimada es                 osteoporosis y síndrome de ovario poliquístico.\nde 1:100.000. Existen dos isoformas de la enzima, he-                   Además, los pacientes con GSDIIIa sufren también\npática y muscular, y se diferencian cuatro subtipos de                afectación muscular cardíaca (casi el 60% de pacien-\nla enfermedad:                                                        tes) y esquelética (aproximadamente el 50%), que se\n                                                                      manifiesta como hipotonía, debilidad, atrofia muscu-\n   •   IIIa: Déficit de las isoformas hepática y muscular             lar, incremento de la creatinkinasa (CK) y miocardiopa-\n       (85%).                                                         tía hipertrófica. Esta última suele aparecer en niños\n   •   IIIb:  Déficit   exclusivo    de    la  isoforma     hepática  mayores antes de los 10 años, y la afectación esquelé-\n       (15%).                                                         tica en la 3ª-4ª décadas de vida. Aunque la gravedad es\n   •   IIIc: Déficit de la actividad glucosidasa de la enzi-          muy variable, en general todas las manifestaciones\n       ma desramificadora (extremadamente rara).                      musculares      empeoran       de   forma     progresiva     con  la\n   •   IIId: Déficit de la actividad transferasa de la enzi-          edad. En los adultos esta afectación muscular es la sin-\n       ma desramificadora (extremadamente rara).                      tomatología       predominante        (la   hepático-metabólica\n---\n                                     Tema 14.      Soporte nutricional en patologías con alteración en el procesamiento…                  219\n\n\n\nmejora), e incluso algunos pacientes son diagnostica-                         Además, estas dietas hiperproteicas y bajas en HC no\ndos a raíz de las manifestaciones a este nivel.                               empeoran las hipoglucemias y sus complicaciones, ya\n   El diagnóstico se fundamenta en las características                        que las proteínas de la dieta y el glicerol se utilizan\nclínicas y bioquímicas (hipoglucemia cetósica, eleva-                         como sustrato gluconeogénico, lo que también evitaría\nción de transaminasas y/ o CK, hipertrigliceridemia), los                     la utilización de las proteínas de la musculatura es-\nhallazgos ecocardiográficos y electromiográficos y se                         quelética y cardíaca para ello. En la mayoría de los ca-\nconfirma mediante estudio genético. En los casos en                           sos publicados se ha seguido el siguiente reparto caló-\ndonde no se halle mutación responsable se cuantifica-                         rico: Proteínas = 20-25% (3 g/kg/día), HC = 15-20%\nrá la actividad enzimática en leucocitos. Solo en caso                        (~4 g/kg/día), lípidos = 60-65% (~6 g/kg/día), con\nde duda se realizará biopsia hepática, muscular o de                          reducción progresiva de los suplementos de almidón\nfibroblastos      para   estudio    histológico,     en   donde se            crudo de maíz. Existe incluso algún trabajo en el que se\naprecia la acumulación de glucógeno anómalo ramifi-                           utiliz\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}